Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21590Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Georgiou, I. | en |
| dc.contributor.author | Seferiadis, K. | en |
| dc.date.accessioned | 2015-11-24T19:15:57Z | - |
| dc.date.available | 2015-11-24T19:15:57Z | - |
| dc.identifier.issn | 0001-5792 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21590 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Anemia, Sickle Cell/blood/*drug therapy | en |
| dc.subject | Child | en |
| dc.subject | Drug Evaluation | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Erythrocyte Indices/drug effects | en |
| dc.subject | Erythropoietin/*administration & dosage | en |
| dc.subject | Female | en |
| dc.subject | Ferrous Compounds/administration & dosage | en |
| dc.subject | Fetal Hemoglobin/analysis/drug effects | en |
| dc.subject | Globins/analysis/*drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Recombinant Proteins/administration & dosage | en |
| dc.subject | Stimulation, Chemical | en |
| dc.subject | Time Factors | en |
| dc.subject | beta-Thalassemia/blood/*drug therapy | en |
| dc.title | Fetal globin stimulation during a short-term trial of erythropoietin in HbS/beta-thalassemia patients | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/7529455 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000204179 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1994 | - |
| heal.abstract | Six sickle cell/beta-thalassemia patients (3 males and 3 females) were treated with 500 U/kg body weight human recombinant erythropoietin (h-rEPO) along with 300 mg/day iron sulfate in two phases, for a period of 90 days. Fetal hemoglobin (HbF) was assayed every 2 weeks and the gamma-chain ratio at three successive intervals during the treatment. All patients showed a moderate to high increase in their HbF values (1.25- to 12-fold). The gamma-chain ratio, as determined by high performance liquid chromatography was found to be unaffected by the HbF increase. Two patients with the newborn gamma-chain ratio, responded faster to the h-rEPO treatment and achieved higher HbF values than the rest of the group. The h-rEPO treatment was very well tolerated and had a positive effect on the general clinical condition of all the patients. | en |
| heal.journalName | Acta Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
